Status:
TERMINATED
Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate
Lead Sponsor:
Hope Pharmaceuticals
Conditions:
Calciphylaxis
Eligibility:
All Genders
18+ years
Brief Summary
This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Ra...
Detailed Description
This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study. In this ST-003 (OF-CALISTA) study, the occurrence of delayed adverse events, standard of care ...
Eligibility Criteria
Inclusion
- Previously enrolled as a patient in ST-001 CALISTA study
- Willing to provide written informed consent
- Willing and able to adhere to all study-related procedures
- Willing to authorize release of medical records
- Willing to authorize collection of medical data from health care providers
- Provide email, home address and phone number where he/she can be reached
Exclusion
- • Patient did not participate in ST-001 CALISTA study
Key Trial Info
Start Date :
October 20 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 9 2018
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03319914
Start Date
October 20 2017
End Date
November 9 2018
Last Update
November 20 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Veterans Administration Medical Center
Albany, New York, United States, 12208
3
Cleveland Clinic
Cleveland, Ohio, United States, 44195